• Rachaneekorn Jantasing Faculty of Allied Health Sciences, Thammasat University
  • Ponlapat Rojnuckarin Division of Hematology, Department of Medicine, Faculty of Medicine, Chulalongkorn University
  • Pakrit Jittapiromsak Unit of Neurological Surgery, Department of Surgery, Faculty of Medicine, Chulalongkorn University
  • Wasan Akarathanawat Chulalongkorn Stroke Center, King Chulalongkorn Memorial Hospital, Thai Red Cross Society
  • Dollapak Apipongrat Division of Hematology, Department of Medicine, Phramongkutklao Hospital and College of Medicine
  • Oytip Nathalang Faculty of Allied Health Sciences, Thammasat University



antiplatelet monitoring, drug effectiveness, dual antiplatelet therapy, flow cytometry, platelet aggregation test


Background: A dual antiplatelet therapy with aspirin and clopidogrel is advised to prevent stent thrombosis. However, the most appropriate assay for evaluating the antiplatelet effects remains undefined.

Objective: This study aimed to assess the efficacy of measuring platelet surface activation markers, CD62P and CD63, using flow cytometry to determine the effectiveness of dual antiplatelet therapy.

Methods: Thirty patients who received aspirin plus clopidogrel before cerebral artery stent implantation and thirty unrelated healthy controls were enrolled. The expression of CD62P and CD63 was measured using flow cytometry. The diagnostic performances were evaluated and compared with the conventional light-transmitted aggregometry (LTA) using 5.0 and 20.0 µM of adenosine di-phosphate (ADP).

Results: The expression ratios of both markers were significantly lower in the patients receiving dual antiplatelet therapy than controls (p < 0.001). The area under the receiver operating characteristic (ROC) curve (AUC) of CD62P using flow cytometry and the LTA using 5.0 and 20.0 µM of ADP were comparable (0.97 vs. 0.95 and 0.97 vs. 0.96, respectively), whereas those of CD63 was lower than the LTA (0.88 vs. 0.96). The sensitivity of CD62P and CD63 were 71.4% and 60.0%, and the specificity of CD62P and CD63 were 100.0% and 96.7%, respectively.

Conclusion: Flow cytometry measurements of CD62P could be utilized to identify the efficacy of dual antiplatelet therapy. Additional studies are suggested to support this issue and its effects on clinical outcomes.


Metrics Loading ...


Thachil J. Antiplatelet therapy - a summary for the general physicians. Clin Med (Lond). 2016; 16: 152-60. DOI:

Grines CL, Bonow RO, Casey DE Jr., Gardner TJ, Lockhart PB, Moliterno DJ, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 2007; 115: 813-8. DOI:

Jain R, Sood J. Antiplatelet therapy in patients with coronary artery stents for noncardiac surgery: Role of thromboelastography. J Anaesthesiol Clin Pharmacol 2011; 27: 537-40. DOI:

Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106. DOI:

CURRENT-OASIS 7 Investigators; Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Eikelboom JW, Fox KA, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010; 363: 930-42. DOI:

Park SJ, Park DW, Kim YH, Kang SJ, Lee SW, Lee CW, et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med 2010; 362: 1374-82. DOI:

Zhou YH, Wei X, Lu J, Ye XF, Wu MJ, Xu JF, et al. Effects of combined aspirin and clopidogrel therapy on cardiovascular outcomes: a systematic review and meta-analysis. PLoS One 2012; 7: e31642. DOI:

Caprie Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348: 1329-39. DOI:

Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Clopidogrel in unstable angina to prevent recurrent events trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502. DOI:

Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke 2006; 37: 577-617. DOI:

Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107: 2908-13. DOI:

ACTIVE Investigators; Connolly S J, Pogue J, Hart R G, Hohnloser S H, Pfeffer M, Chrolavicius S, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009; 360: 2066-78. DOI:

Kulik A, Le May MR, Voisine P, Tardif JC, Delarochelliere R, Naidoo S, et al. Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) Trial. Circulation 2010; 122: 2680-7. DOI:

Tamura T, Sakaeda T, Kadoyama K, Okuno Y. Aspirin- and clopidogrel-associated bleeding complications: data mining of the public version of the FDA adverse event reporting system, AERS. Int J Med Sci 2012; 9: 441-6. DOI:

Diener HC, Weber R. Clopidogrel added to aspirin adds no benefit but bleeding risk in patients with recent lacunar stroke. Stroke 2013; 44: 861-3. DOI:

Krishnan K, Nguyen TN, Appleton JP, Law ZK, Caulfied M, Cabrera CP, et al. Antiplatelet resistance: A review of concepts, mechanisms, and implications for management in acute ischemic stroke and transient ischemic attack. Stroke Vasc Interv Neurol 2023; 3: e000576. DOI:

Guirgis M, Thompson P, Jansen S. Review of aspirin and clopidogrel resistance in peripheral arterial disease. J Vasc Surg 2017; 66: 1576-86. DOI:

Karunawan NH, Pinzon RT. Prevalence of aspirin and clopidogrel resistance in patients with recurrent ischaemic cerebrovascular disease. Eur Cardiol 2021; 16: e72. DOI:

Marginean A, Banescu C, Scridon A, Dobreanu M. Antiplatelet therapy resistance - concept, mechanisms and platelet function tests in intensive care facilities. J Crit Care Med (Targu Mures). 2016; 2: 6-15. DOI:

Lordkipanidze M. Platelet function tests. Semin Thromb Hemost 2016; 42: 258-67. DOI:

Lordkipanidze M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007; 28: 1702-8. DOI:

Grau A J, Reiners S, Lichy C, Buggle F, A. R. Platelet function under aspirin, clopidogrel, and both after ischemic stroke: a case-crossover study. Stroke 2003; 34: 849-54. DOI:

Lu BC, Shi XJ, Liang L, Dong N, Liu ZZ. Platelet surface CD62p and serum vitamin D levels are associated with clopidogrel resistance in Chinese patients with ischemic stroke. J Stroke Cerebrovasc Dis 2019; 28: 1323-8. DOI:

Cattaneo M. Light transmission aggregometry and ATP release for the diagnostic assessment of platelet function. Semin Thromb Hemost 2009; 35: 158-67. DOI:

Carubbi C, Masselli E, Gesi M, Galli D, Mirandola P, Vitale M, et al. Cytofluorimetric platelet analysis. Semin Thromb Hemost 2014; 40: 88-98. DOI:

Khan H, Kanny O, Syed MH, Qadura M. Aspirin resistance in vascular disease: a review highlighting the critical need for improved point-of-care testing and personalized therapy. Int J Mol Sci 2022; 23: 11317. DOI:

Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ruven HJ, Bal ET, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010; 303: 754-62. DOI:

Nagy B Jr, Debreceni IB, Kappelmayer J. Flow cytometric investigation of classical and alternative platelet activation markers. EJIFCC 2013; 23: 124-34.

Choudhury A, Chung I, Blann AD, Lip GY. Platelet surface CD62P and CD63, mean platelet volume, and soluble/platelet P-selectin as indexes of platelet function in atrial fibrillation: a comparison of "healthy control subjects" and "disease control subjects" in sinus rhythm. J Am Coll Cardiol 2007; 49: 1957-64. DOI:

Cha JK, Jo WS, Shin HC, Bae HR, Ho JM, Kim JW. Increased platelet CD63 and P-selectin expression persist in atherosclerotic ischemic stroke. Platelets 2004; 15: 3-7. DOI:

Differences in the expression ratios of (A.) CD62P and (B.) CD63 among patients and controls




How to Cite

Jantasing R, Rojnuckarin P, Jittapiromsak P, Akarathanawat W, Apipongrat D, Nathalang O. MEASUREMENT OF PLATELET ACTIVATION MARKERS CD62P AND CD63 TO DETERMINE THE EFFICIENCY OF DUAL THERAPY WITH ASPIRIN AND CLOPIDOGREL: A PRELIMINARY STUDY. J Southeast Asian Med Res [Internet]. 2024 May 24 [cited 2024 Jun. 16];8:e0207. Available from:



Original Articles

Most read articles by the same author(s)

Similar Articles

1 2 3 4 > >> 

You may also start an advanced similarity search for this article.